Rosiglitazone treatment reduces diabetic neuropathy in streptozotocin- treated DBA/2J mice

Endocrinology

Volumn 149, Issue 10, 2008, Pages 4928-4937

  Wiggin, Timothy D ^a   Kretzler, Matthias ^a   Pennathur, Subramaniam ^a   Sullivan, Kelli A ^a   Brosius, Frank C ^a   Feldman, Eva L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN SENSITIZING AGENT; RNA; ROSIGLITAZONE; STREPTOZOCIN; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIET RESTRICTION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; GENE EXPRESSION; HYPERGLYCEMIA; HYPOALGESIA; MEDICAL INFORMATICS; MOUSE; NERVE CONDUCTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BINDING; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; FEMALE; GENE EXPRESSION; GENOMICS; GROWTH HORMONE; HYPERALGESIA; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED DBA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXIDATIVE STRESS; PROMOTER REGIONS (GENETICS); THIAZOLIDINEDIONES;

EID: 53249121822     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-0869     Document Type: Article

References (59)

1. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D, American Diabetes Association 2005 Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 28:956-962
2. Said G, Goulon-Goeau C, Slama G, Tchobroutsky G 1992 Severe early-onset polyneuropathy in insulin-dependent diabetes mellitus - a clinical and pathological study. N Engl J Med 326:1257-1263
3. Bhatia V, Viswanathan P 2006 Insulin resistance and PPAR insulin sensitizers. Curr Opin Investig Drugs 7:891-897
4. Chang AY, Wyse BM, Gilchrist BJ, Peterson T, Diani AR 1983 Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats. Diabetes 32:830-838
5. Chang AY, Wyse BM, Gilchrist BJ 1983 Ciglitazone, a new hypoglycemic agent. II. Effect on glucose and lipid metabolisms and insulin binding in the adipose tissue of C57BL/6J-ob/ob and -+/? mice. Diabetes 32:839-845
6. Fujita T, Sugiyama Y, Taketomi S, Sohda T, Kawamatsu Y, Iwatsuka H, Suzuoki Z 1983 Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes 32:804-810
7. Vasudevan AR, Balasubramanyam A 2004 Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol Ther 6:850-863
8. Yamagishi SI, Ogasawara S, Mizukami H, Yajima N, Wada RI, Sugawara A, Yagihashi S 2008 Correction of protein kinase C activity and macrophage migration in peripheral nerve by pioglitazone, peroxisome proliferator activated-γ-ligand, in insulin-deficient diabetic rats. J Neurochem 104:491-499
9. Desvergne B, Wahli W 1999 Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20:649-688
10. Sears DD, Hsiao A, Ofrecio JM, Chapman J, He W, Olefsky JM 2007 Selective modulation of promoter recruitment and transcriptional activity of PPARγ. Biochem Biophys Res Commun 364:515-521
11. Dumasia R, Eagle KA, Kline-Rogers E, May N, Cho L, Mukherjee D 2005 Role of PPAR-γ agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: a cardiovascular perspective. Curr Drug Targets 5:377-386
12. Giannini S, Serio M, Galli A 2004 Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J Endocrinol Invest 27:982-991
13. Ghosh S, Patel N, Rahn D, McAllister J, Sadeghi S, Horwitz G, Berry D, Wang KX, Swerdlow RH 2007 The thiazolidinedione pioglitazone alters mitochondrial function in human neuron-like cells. Mol Pharmacol 71:1695-1702
14. Hwang J, Kleinhenz DJ, Rupnow HL, Campbell AG, Thule PM, Sutliff RL, Hart CM 2007 The PPARγ ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice. Vascul Pharmacol 46:456-462
15. Qiang X, Satoh J, Sagara M, Fukuzawa M, Masuda T, Sakata Y, Muto G, Muto Y, Takahashi K, Toyota T 1998 Inhibitory effect of troglitazone on diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetologia 41:1321-1326
16. Nagasaka Y, Kaku K, Nakamura K, Kaneko T 1995 The new oral hypoglycemic agent, CS-045, inhibits the lipid peroxidation of human plasma low density lipoprotein in vitro. Biochem Pharmacol 50:1109-1111
17. Deeg MA, Buse JB, Goldberg RB, Kendall DM, Zagar AJ, Jacober SJ, Khan MA, Perez AT, Tan MH 2007 Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 30:2458-2464
18. Singh S, Loke YK, Furberg CD 2007 Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298:1189-1195
19. Faich GA, Moseley RH 2001 Troglitazone (Rezulin) and hepatic injury. Pharmacoepidemiol Drug Saf 10:537-547
20. Sullivan KA, Hayes JM, Wiggin TD, Backus C, Su Oh S, Lentz SI, Brosius 3rd F, Feldman EL 2007 Mouse models of diabetic neuropathy. Neurobiol Dis 28:276-285
21. Vincent AM, Russell JW, Sullivan KA, Backus C, Hayes JM, McLean LL, Feldman EL 2007 SOD2 protects neurons from injury in cell culture and animal models of diabetic neuropathy. Exp Neurol 208:216-227
22. Malencik DA, Sprouse JF, Swanson CA, Anderson SR 1996 Dityrosine: preparation, isolation, and analysis. Anal Biochem 242:202-213
23. Pennathur S, Ido Y, Heller JI, Byun J, Danda R, Pergola P, Williamson JR, Heinecke JW 2005 Reactive carbonyls and polyunsaturated fatty acids produce a hydroxyl radical-like species: a potential pathway for oxidative damage of retinal proteins in diabetes. J Biol Chem 280:22706-22714
24. Pennathur S, Bergt C, Shao B, Byun J, Kassim SY, Singh P, Green PS, McDonald TO, Brunzell J, Chait A, Oram JF, O'Brien K, Geary RL, Heinecke JW 2004 Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J Biol Chem 279:42977-42983
25. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE, Myers RM, Speed TP, Akil H, Watson SJ, Meng F 2005 Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 33:e175
26. Baldi P, Long AD 2001 A Bayesian framework for the analysis of microarray expression data: regularized t-test and statistical inferences of gene changes. Bioinformatics 17:509-519
27. Dennis Jr G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA 2003 DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4:P3
28. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP 2005 Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545-15550
29. Vincent AM, Russell JW, Low P, Feldman EL 2004 Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 25:612-628
30. Qi Z, Fujita H, Jin J, Davis LS, Wang Y, Fogo AB, Breyer MD 2005 Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes 54:2628-2637
31. Park SW, Yi JH, Miranpuri G, Satriotomo I, Bowen K, Resnick DK, Vemuganti R 2007 Thiazolidinedione class of peroxisome proliferator- activated receptor γ agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Ther 320:1002-1012
32. Saini AK, Kumar HSA, Sharma SS 2007 Preventive and curative effect of edaravone on nerve functions and oxidative stress in experimental diabetic neuropathy. Eur J Pharmacol 568:164-172
33. Kumar A, Kaundal RK, Iyer S, Sharma SS 2007 Effects of resveratrol on nerve functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy. Life Sci 80:1236-1244
34. Ueno Y, Horio F, Uchida K, Naito M, Nomura H, Kato Y, Tsuda T, Toyokuni S, Osawa T 2002 Increase in oxidative stress in kidneys of diabetic Akita mice. Biosci Biotechnol Biochem 66:869-872
35. May JM, Qu ZC 2000 Troglitazone protects human erythrocytes from oxidant damage. Antioxid Redox Signal 2:243-250
36. Price SA, Zeef LA, Wardleworth L, Hayes A, Tomlinson DR 2006 Identification of changes in gene expression in dorsal root ganglia in diabetic neuropathy: correlation with functional deficits. J Neuropathol Exp Neurol 65:722-732
37. Tremp GL, Boquet D, Ripoche MA, Cognet M, Lone YC, Jami J, Kahn A, Daegelen D 1989 Expression of the rat L-type pyruvate kinase gene from its dual erythroid- and liver-specific promoter in transgenic mice. J Biol Chem 264:19904-19910
38. Yamada K, Noguchi T, Miyazaki J, Matsuda T, Takenaka M, Yamamura K, Tanaka T 1990 Tissue-specific expression of rat pyruvate kinase L/chloramphenicol acetyltransferase fusion gene in transgenic mice and its regulation by diet and insulin. Biochem Biophys Res Commun 171:243-249
39. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Kloting I, Morcos M, Hofmann M, Tritschler H, Weigle B, Kasper M, Smith M, Perry G, Schmidt AM, Stern DM, Haring HU, Schleicher E, Nawroth PP 2001 Diabetes-associated sustained activation of the transcription factor nuclear factor-κB. Diabetes 50:2792-2808
40. Schmid H, Boucherot A, Yasuda Y, Henger A, Brunner B, Eichinger F, Nitsche A, Kiss E, Bleich M, Grone HJ, Nelson PJ, Schlondorff D, Cohen CD, Kretzler M 2006 Modular activation of nuclear factor-κB transcriptional programs in human diabetic nephropathy. Diabetes 55:2993-3003
41. Ruiz-Ortega M, Lorenzo O, Egido J 2000 Angiotensin III increases MCP-1 and activates NF-κB and AP-1 in cultured mesangial and mononuclear cells. Kidney Int 57:2285-2298
42. Mezzano SA, Barria M, Droguett MA, Burgos ME, Ardiles LG, Flores C, Egido J 2001 Tubular NF-κB and AP-1 activation in human proteinuric renal disease. Kidney Int 60:1366-1377
43. Burnand RC, Price SA, McElhaney M, Barker D, Tomlinson DR 2004 Expression of axotomy-inducible and apoptosis-related genes in sensory nerves of rats with experimental diabetes. Brain Res Mol Brain Res 132:235-240
44. Moreno-Aliaga MJ, Swarbrick MM, Lorente-Cebrian S, Stanhope KL, Havel PJ, Martinez JA 2007 Sp1-mediated transcription is involved in the induction of leptin by insulin-stimulated glucose metabolism. J Mol Endocrinol 38:537-546
45. Kaczynski J, Cook T, Urrutia R 2003 Sp1- and Kruppel-like transcription factors. Genome Biol 4:206
46. Medvedev AV, Snedden SK, Raimbault S, Ricquier D, Collins S 2001 Transcriptional regulation of the mouse uncoupling protein-2 gene. Double E-box motif is required for peroxisome proliferator-activated receptor-γ- dependent activation. J Biol Chem 276:10817-10823
47. Chung SS, Choi HH, Cho YM, Lee HK, Park KS 2006 Sp1 mediates repression of the resistin gene by PPARγ agonists in 3T3-L1 adipocytes. Biochem Biophys Res Commun 348:253-258
48. Deng T, Shan S, Li PP, Shen ZF, Lu XP, Cheng J, Ning ZQ 2006 Peroxisome proliferator-activated receptor-γ transcriptionally up-regulates hormone-sensitive lipase via the involvement of specificity protein-1. Endocrinology 147:875-884
49. Han S, Ritzenthaler JD, Rivera HN, Roman J 2005 Peroxisome proliferator-activated receptor-γ ligands suppress fibronectin gene expression in human lung carcinoma cells: involvement of both CRE and Sp1. Am J Physiol Lung Cell Mol Physiol 289:L419-L428
50. Drori S, Girnun GD, Tou L, Szwaya JD, Mueller E, Xia K, Shivdasani RA, Spiegelman BM 2005 Hic-5 regulates an epithelial program mediated by PPARγ. Genes Dev [Erratum (2005) 19:875] 19:362-375
51. Chintharlapalli S, Papineni S, Jutooru I, McAlees A, Safe S 2007 Structure-dependent activity of glycyrrhetinic acid derivatives as peroxisome proliferator-activated receptor γ agonists in colon cancer cells. Mol Cancer Ther 6:1588-1598
52. Cibelli G, Policastro V, Rossler OG, Thiel G 2002 Nitric oxide-induced programmed cell death in human neuroblastoma cells is accompanied by the synthesis of Egr-1, a zinc finger transcription factor. J Neurosci Res 67:450-460
53. Berger P, Niemann A, Suter U 2006 Schwann cells and the pathogenesis of inherited motor and sensory neuropathies (Charcot-Marie-Tooth disease). Glia 54:243-257
54. Decker L, Desmarquet-Trin-Dinh C, Taillebourg E, Ghislain J, Vallat JM, Charnay P 2006 Peripheral myelin maintenance is a dynamic process requiring constant Krox20 expression. J Neurosci 26:9771-9779
55. Chintharlapalli S, Papineni S, Baek SJ, Liu S, Safe S 2005 1,1-Bis(3′-indolyl)-1-(p-substitutedphenyl)methanes are peroxisome proliferator-activated receptor γ agonists but decrease HCT-116 colon cancer cell survival through receptor-independent activation of early growth response-1 and nonsteroidal anti-inflammatory drug-activated gene-1. Mol Pharmacol 68:1782-1792
56. Bilban M, Bach FH, Otterbein SL, Ifedigbo E, de Costa d'Avila JC, Esterbauer H, Chin BY, Usheva A, Robson SC, Wagner O, Otterbein LE 2006 Carbon monoxide orchestrates a protective response through PPARγ. Immunity 24:601-610
57. Okada M, Yan SF, Pinsky DJ 2002 Peroxisome proliferator-activated receptor-γ (PPAR-γ) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets. FASEB J 16:1861-1868
58. Thellmann M, Hatzold J, Conradt B 2003 The Snail-like CES-1 protein of C. elegans can block the expression of the BH3-only cell-death activator gene egl-1 by antagonizing the function of bHLH proteins. Development 130:4057-4071
59. Nam S, Jin YH, Li QL, Lee KY, Jeong GB, Ito Y, Lee J, Bae SC 2002 Expression pattern, regulation, and biological role of runt domain transcription factor, run, in Caenorhabditis elegans. Mol Cell Biol 22:547-554